Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Changes in nutrition and growth status in young children in the first 12 weeks of ivacaftor therapy.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 1 Nov 2023

Tindall Alyssa, Bass Rosara, Maqbool Asim, Stallings Virginia A

Abstract excerpt

BACKGROUND: Highly effective CFTR modulators improve nutritional status and are of particular importance among younger children experiencing rapid growth. This study was designed to examine CFTR modulator associated changes in nutritional and other extrapulmonary outcomes in children 4-24 months of age with ivacaftor treatment over 12 weeks. METHODS: Children 4-24 months were recruited from US and Canadian CF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Bile Acids and Salts

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Canada

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Fatty Acids

Share to Infant

Share to Nutritional Status

Source

Open in PubMed Open full text

Identifiers

PMID: 37438197
DOI: 10.1016/j.jcf.2023.04.010
PMCID: PMC10776802

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Changes in nutrition and growth status in young children in the first 12 weeks of ivacaftor therapy.PMID 37438197Read ↗

Body mass index and nutritional intake following Elexacaftor/Tezacaftor/Ivacaftor modulator therapy in adults with cystic fibrosis.Semantic proximity Read ↗

Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations.Semantic proximity Read ↗

Evolving Nutritional Needs in Cystic FibrosisSemantic proximity Read ↗

Impact of elexacaftor/tezacaftor/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index.Semantic proximity Read ↗

Updates in Nutrition Management of Cystic Fibrosis in the Highly Effective Modulator Era.Semantic proximity Read ↗

The Impact of Highly Effective CFTR Modulators on Growth and Nutrition Status.Semantic proximity Read ↗

Effect of CFTR Modulators on Anthropometric Parameters in Individuals with Cystic Fibrosis: An Evidence Analysis Center Systematic Review.Semantic proximity Read ↗

Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D.Semantic proximity Read ↗

Impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in children with cystic fibrosis.Semantic proximity Read ↗

Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy.Semantic proximity Read ↗

Impact of elexacaftor/tezacaftor/ivacaftor on vitamin D absorption in cystic fibrosis patients.Semantic proximity Read ↗

Growth trajectories in Pediatric Cystic Fibrosis Population on Elexacaftor-Tezacaftor-Ivacaftor: Real-Life DataSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.